GSK is once again making headlines.

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic collaboration with LTZ Therapeutics, advancing novel myeloid cell engagers in oncology, along with launching six new research programs in a collaborative research effort with Fleming Initiative.

GSK and LTZ Therapeutics
GSK announced a strategic research collaboration with LTZ Therapeutics aiming to advance the development of novel myeloid cell engagers (MCEs), addressing a significant unmet need in oncology.1 The research collaboration aims to develop four potential first-in-class MCE therapies targeting both hematologic cancers and solid tumors.1 Per the terms of the agreement, GSK is granted an exclusive option for worldwide licensing development, along with commercial rights for these pre-clinical therapies.

GSK is shifting its focus towards MCEs due to their emergence as a class of immuno-oncology treatments designed to use the body’s own immune system to recognize and kill tumor cells, providing a novel approach to target cancers with a favorable safety profile.1 Currently, LTZ’s MCE platform has displayed potential in pre-clinical data on targeted anti-cancer activity in multiple tumor types, and while other modalities have shown efficacy, it can be associated with significant side effects requiring inpatient monitoring that limit community use where most patients receive care.1

Hesham Abdullah, senior vice president and global head of oncology and R&D at GSK, spoke about the collaboration effort, saying, “This collaboration builds on GSK’s targeted investment in next-generation technologies to advance cancer medicines with transformative potential. By combining our scientific expertise with LTZ’s innovative immune-engager platform, we aim to accelerate first-in-class myeloid cell engager therapies in hematologic cancers and solid tumors to transform outcomes with a safety profile to enable broad community access for people living with cancer.”

GSK and Fleming Initiative
Along with its collaboration with LTZ, GSK announced a research collaboration with Fleming Initiative, launching six new research programs titled “Grand Challenges.”The Grand Challenges are expected to harness some of the best scientific expertise and pair it with the latest technologies, including advanced AI, to discover new ways to slow the progress of antimicrobial resistance (AMR).2

The six new research programs are expected to focus on the following:

Discovery of new antibiotics for Gram-negative bacterial infections.
Accelerating new drug discoveries to combat fungal infections.
Using Staphylococcus aureus to understand how immune systems respond to drug-resistant bacteria.
Creating AI models with disease surveillance and environmental data to predict how drug-resistant pathogens emerge and spread
Using a clinical trial to improve antibiotics prescriptions.
Informing policy and public engagement using international research data and insights, embedding preventative interventions, accelerating continued R&D, and amplifying societal and government action to get ahead of AMR.

“I’m delighted to combine GSK’s leadership in antimicrobial science with world-leading research at Imperial College London. Together, with scaled datasets, emerging drug modalities and AI-driven models, we will open up new approaches for the discovery of novel antibiotics as well as anticipate and outpace the development of resistance to transform the treatment and prevention of serious infections. Currently, GSK has a promising portfolio of relevant assets in development, many targeting pathogens identified as priorities by WHO and U.S. CDC. We will continue to be a leader in inspiring much more collective action, across industry, academia and policy and I believe our partnership with the Fleming Initiative is an important new step in that direction,” said Tony Wood, chief scientific officer, GSK.

Sources
GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology GSK November 19, 2025 https://www.gsk.com/en-gb/media/press-releases/gsk-and-ltz-announce-strategic-collaboration-to-advance-novel-myeloid-cell-engagers-in-oncology/
GSK and Fleming Initiative scientists unite to target AMR with advanced AI GSK November 18, 2025 https://www.gsk.com/en-gb/media/press-releases/gsk-and-fleming-initiative-scientists-unite-to-target-amr-with-advanced-ai/